featured-image

Adam Gault Citi has downgraded Bio-Techne ( NASDAQ: TECH ) to neutral, primarily due to valuation following a run-up in its share price in the wake of its fiscal Q3 earnings report. The investment bank added it also had “some uncertainty around management’s optimism regarding biopharma funding and China vs. peers.

” Citi also noted TECH’s relatively high multiple relative to margin expansion in comparison to peers in its coverage universe. “While we acknowledge TECH has typically carried a premium vs. this index, the magnitude of the premium currently makes it more challenging to argue for continued outperformance,” Citi said.



Citi maintained its price target of $85 for the stock. More on Bio-Techne Bio-Techne Corporation (TECH) Q3 2024 Earnings Call Transcript Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence Bio-Techne Non-GAAP EPS of $0.48 beats by $0.

02, revenue of $303.4M beats by $10.7M Bio-Techne Q3 2024 Earnings Preview Seeking Alpha’s Quant Rating on Bio-Techne.

Back to Health Page